Revenues are also down, with a handful of large biotechs like Amgen (AMGN) making the lion's share of money while the majority of biotechs struggle to raise funds, especially for early stage projects.

营收也出现下滑，安进(Amgen)等少数几个大型生物技术公司掳走了大部分资金，而其他绝大多数的生物技术公司则面临着筹资困难，处于早期阶段的项目更是如此。

youdao

Revenues are also down, with a handful of large biotechs like Amgen (AMGN) making the lion's share of money while the majority of biotechs struggle to raise funds, especially for early stage projects.

营收也出现下滑，安进(Amgen)等少数几个大型生物技术公司掳走了大部分资金，而其他绝大多数的生物技术公司则面临着筹资困难，处于早期阶段的项目更是如此。

youdao